Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
19 Dezembro 2024 - 2:00PM
Jean-Paul Kress to join Sanofi's Board of
Directors
Paris, December 19, 2024.
Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress
as an independent director as of January 1, 2025, replacing Gilles
Schnepp who has decided to leave the Board at the end of 2024.
Jean-Paul Kress will hold his position for the remainder of Gilles
Schnepp's term of office and his appointment will be subject to
ratification at the next Ordinary Shareholders' Meeting of
Sanofi.
Jean-Paul Kress, M.D., served
as the CEO of MorphoSys from 2019 until it was acquired by Novartis
in 2024. He led the company in its mission – More life for people
with cancer – and has spearheaded its transformation into a global
biopharmaceutical company developing and commercializing novel
cancer medicines. Prior to this, Jean-Paul Kress was the CEO of
Syntimmune, where he sharpened the company’s focus on late-stage
clinical development in auto-immune diseases until the company’s
acquisition by Alexion. He has also held several senior leadership
roles at other pharmaceutical companies in the US and in Europe.
Jean-Paul Kress served as Chairman of the Board of Directors at
ERYTECH Pharma and was a member of Sarepta Therapeutics’ Board of
Directors. He received his M.D. from Faculté Necker-Enfants Malades
in Paris and Master of Sciences in molecular and cellular
pharmacology from Ecole normale supérieure (Ulm) in Paris.
Frédéric OudéaChairman of the
Board of Directors"I extend my heartfelt gratitude to Gilles
Schnepp for his unwavering dedication to the Board, and
particularly his pivotal contribution to the evolution of the
company’s governance in 2023. The Board is delighted to welcome
Jean-Paul Kress as its newest director. With over 30 years of
diverse executive experience in the pharmaceutical sector, spanning
large corporations and biotech firms, Jean-Paul brings exceptional
global expertise to the Board. His insights will be invaluable in
guiding the company’s ongoing strategic evolution in the
biopharmaceutical field."
Regarding the organization of the Board
Committees, Patrick Kron will take over as Chairman of the
Appointments, Governance and CSR Committee and Jean-Paul Kress will
join the Strategy Committee and the Scientific Committee.
About Sanofi We are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people’s lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions. Sanofi is
listed on EURONEXT: SAN and NASDAQ: SNY
Media RelationsSandrine
Guendoul | + 33 6 25 09 14 25 |
sandrine.guendoul@sanofi.com Evan Berland | +1 215
432 0234 | evan.berland@sanofi.com Nicolas
Obrist | + 33 6 77 21 27 55 | nicolas.obrist@sanofi.com
Léo Le Bourhis | + 33 6 75 06 43 81 |
leo.lebourhis@sanofi.com Victor Rouault | +
33 6 70 93 71 40 | victor.rouault@sanofi.com Timothy
Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor RelationsThomas Kudsk
Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 |
alize.kaisserian@sanofi.com Felix Lauscher | + 1
908 612 7239 | felix.lauscher@sanofi.com Keita
Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com Tarik Elgoutni | + 1 617
710 3587 | tarik.elgoutni@sanofi.com Thibaud
Châtelet | + 33 6 80 80 89 90 |
thibaud.chatelet@sanofi.com
- 2024_12_19_GPR_Board appointment_ENG
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Sanofi (EU:SAN)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
